Tailored total lymphoid irradiation in heart transplant patients: 10-years experience of one center
To assess safety and efficacy of tailored total lymphoid irradiation (tTLI) in cardiac transplant patients.
Methods: A total of seven patients, of which five had recalcitrant cellular cardiac allograft rejection (RCCAR), confirmed by endomyocardial biopsies, and two had side effects of immunosuppressive drug therapy, were all treated with tTLI. tTLI was defined by the adjustment of both the fraction interval and the final irradiation dosage both being dependent on the patients general condition, irradiation-dependent response, and the white blood and platelet counts.
A mean dose of 6.4 Gy (range, 1.6 - 8.8 Gy) was given. Median follow-up was 7 years (range, 1.8 - 12.2 years).
Results: tTLI was well tolerated.
Two patients experienced a severe infection during tTLI (pneumocystis jirovecii pneumonia, urosepsis and generalized herpes zoster) and one patient developed a lymphoproliferative disorder after tTLI. The rate of rejection episodes before tTLI was 0.43 episodes/patient/month and decreased to 0.02 episodes/patient/month after tTLI (P<.001).
At the end of the observation time, all patients except one were alive.
Conclusions: tTLI is a useful treatment strategy for the management of RCCAR and in patients with significantside effects of immunosuppressive drug therapy. In this series tTLI demonstrated significantly decreased rejection rates without causing relevant treatment-related toxicity.
Author: Pirus GhadjarDaniela JoosMichele MartinelliRoger HullinMarcel ZwahlenKristina LoesslThierry CarrelDaniel AebersoldPaul Mohacsi
Credits/Source: Radiation Oncology 2010, 5:3
Published on: 2010-01-16
Copyright by the authors listed above - made available via BioMedCentral (Open Access). Please
make sure to read our disclaimer prior to contacting 7thSpace Interactive. To contact our editors, visit our online helpdesk. If you wish submit your own press release, click here.
Social Bookmarking
RETWEET This! | Digg this! | Post to del.icio.us | Post to Furl | Add to Netscape | Add to Yahoo! | Rojo
|
|
